Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16173906 | 0.89 | MCL1 (0.46) | FAAHMCL1RAB9AHPGDNPC1 | |
| SCHEMBL13007887 | 0.88 | MEN1 (0.40) | FAAHRAB9AHPGDNPC1SMN1; SMN2 | |
| SCHEMBL27410666 | 0.86 | FAAH (0.33) | FAAHMCL1RAB9AHPGDNPC1 | |
| SCHEMBL14392989 | 0.83 | CTSD (0.43) | FAAHMCL1RAB9AHPGDNPC1 | |
| SCHEMBL26227327 | 0.83 | MCL1 (0.45) | FAAHMCL1RAB9AHPGDNPC1 | |
| SCHEMBL13707242 | 0.82 | — | — | |
| SCHEMBL14415956 | 0.80 | FAAH (0.43) | FAAHMCL1RAB9AHPGDNPC1 | |
| SCHEMBL13402313 | 0.80 | CES2 (0.42) | FAAHMCL1RAB9AHPGDNPC1 | |
| SCHEMBL15616271 | 0.80 | MCL1 (0.40) | FAAHMCL1RAB9AHPGDNPC1 | |
| SCHEMBL14393226 | 0.80 | RAB9A (0.43) | FAAHMCL1RAB9AHPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3797796-A1 | ANTIBODY-DRUG CONJUGATE AND APPLICATION THEREOF | Mabplex International, Ltd. (CN) | 2021-03-31 | — | — | EP | disclosed |
| US-9981043-B2 | Analgesic conjugates | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-05-29 | — | — | US | disclosed |
| US-8197793-B2 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2012-06-12 | — | — | US | disclosed |
| US-8197793-B2 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2012-06-12 | — | — | US | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | GE HEALTHCARE AS (NO) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068139-A1 | Methods of radiofluorination of biologically active vectors | DOHH, VGF, HNRNPH3 | FAAH 216/4885MCL1 558/4885RAB9A 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.